The search for a specific inhibitor of the BCR-ABL tyrosine kinase have resulted in the identification of the specific inhibitor imatinib mesylate (STI571), which has now become the standard first-line therapy in patients with CP-CML [10,11]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.